{'fraction_non_alphanumeric': 0.04241435562805873, 'fraction_numerical': 0.022838499184339316, 'mean_word_length': 5.324742268041237, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low Human Immunodeficiency Virus (HIV) Testing Rates and No HIV Preexposure Prophylaxis Prescribed Among Female Patients Diagnosed With a Sexually Transmitted Infection, 2017-2018.

METHODS We analyzed data from both the IBM MarketScan commercial and Medicaid insurance databases. Nonpregnant female patients aged 15–64 years without a prior HIV diagnosis who had a diagnosis of gonorrhea or syphilis (Appendix 1, available online at http://links.lww.com/AOG/C94) in 2017 and who were continuously enrolled in their health insurance plans for at least 6 months before and 11 months after their first sexually transmitted infection (STI) diagnosis date were included in the analysis (Appendix 2, available online at http://links.lww.com/AOG/C94). To estimate associations between HIV testing (Appendix 3, available online at http://links.lww. com/AOG/C94) and female patients’ characteristics and STI diagnoses, we performed multivariate logistic regression analyses for those with commercial insurance and those with Medicaid insurance separately. In the commercial model, we included age, U.S. geographic region, and urban compared with rural location as covariates; in the Medicaid model, we included age and race–ethnicity.